Compare Eli Lilly And Co (LLY) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NetFlix Inc — how do they compare? Eli Lilly And Co trades at $1,141 (market cap $1.02T), while NetFlix Inc trades at $67.35 (market cap $281.48B). The key difference: Eli Lilly And Co is far larger — about 3.6× NetFlix Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| LLY | NFLX | |
|---|---|---|
Market Cap | $1.02T | $281.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $126.33 |
52-Week Low | $625.65 | $67.60 |
Enterprise Value | $1.06T | $286.66B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Netflix (NFLX) trades at $67.60, down 1.96% on the day and near its 52-week low, reflecting bearish technical signals despite strong fundamentals. The company reported robust Q2 2026 EPS of $0.80, beating expectations, with revenue growth accelerating to $45.18B in 2025. Analyst consensus remains bullish with a $90.47 price target, but recent news highlights stock weakness amid advertising business expansion and competitive pressures.
Outlook: Long-term growth potential is supported by scalable ad revenue and global content dominance, but near-term risks include market sentiment shifts and execution challenges. Investors face a divergence between strong financial performance and technical bearishness, requiring careful risk assessment amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
